Zacks Investment Research downgraded shares of STAR SCIENTIFIC (STSI) from OUTPERFORM to NEUTRAL on January 31, 2013, with a target price of $2.60.
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism and lifestyle. The Company, recently, has been focusing primarily on the anti-inflammatory aspects of anatabine, an alkaloid found in the Solanacea family of plants, which includes potatoes, tomatoes, and eggplants, and the potential for licensing opportunities related to its products and underlying technology. Currently, the Company manufactures and sells a dietary supplement, Anatabloc, for anti-inflammatory support, as well as an anatabine-based cosmetic cream that improves the appearance of the skin. In addition, Rock Creek Pharmaceuticals has been engaged in the development of other dietary supplements and pharmaceutical products, particularly products that have a botanical-based component and that are designed to provide nutritional support in a range of conditions, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, and Hashimoto's thyr
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on STAR SCIENTIFIC (STSI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment